Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia

Inclusion Criteria: 1. Patients who had undergone a Kasai portoenterostomy for BA, and who were postoperatively managed in our outpatient clinic 2. Patients who made informed consent for clinical study of COX-2 inhibitor 3. Patients who were followed up with liver fibroscan study 4. Patients who were over 2 years old and less than or equal to 17 years Exclusion Criteria: 1. Patients who were impossible to join the clinical study because of their underlying diseases (renal disease, liver disease, diabetes mellitus, GI disease, including bleeding, perforation, or ulceration, etc.) other than biliary atresia, ii) H. pylori infection, iii) asthma, iv) nasal polyp, v) hypertension, vi) hematologic disease, vii) coagulopathy, viii) cardiac disease, ix) vascular disease 2. Patients who did not get the drug (COX-2 inhibitor) 3. Patients who did not check liver fibroscan 4. Patients who were impossible to join the clinical study because of their complication after Kasai portoenterostomy 5. Patients who did not make informed consent for clinical study of COX-2 inhibitor 6. Patients who cannot take drug because of their allergy, skin disease or asthma attack to drug (COX-2 inhibitor) 7. Patients who were decided to withdraw because of their severe drug adverse events